VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
OMEROmeros Corporation
$8.67$627M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksOMERBalance Sheet

Omeros Corporation (OMER) Balance Sheet

19Y historyFree accessUpdated daily

Omeros maintains a highly leveraged capital structure with $310.6 million in total debt and a persistent negative equity position that reached $63.3 million in 2026Q1.

OMER Balance Sheet

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07
Total Current Assets180.35M215.67M134.12M217.9M443.24M247.96M151.28M103.75M89.87M108.37M60.26M37.15M9.16M14.82M24.7M25.95M43.75M60.66M20.48M24.46M
Cash & Short-Term Investments135.32M171.8M90.13M171.85M194.92M157.27M134.95M60.79M60.5M83.75M45.33M28.26M6.89M14.1M22.35M24.57M41.99M60.3M19.98M24.08M
Cash Only1.91M9.66M3.4M7.11M11.01M100.81M10.5M3.08M5.86M3.39M2.22M1.36M354K1.38M1.52M4M3.28M820K12.73M5.92M
Short-Term Investments133.41M162.14M86.73M164.74M183.91M56.46M124.45M57.7M54.64M80.36M43.11M26.9M6.53M12.72M20.83M20.57M38.72M59.48M7.26M18.16M
Accounts Receivable37.51M36.27M36.82M6.72M242.02M82.47M3.84M35.19M22.82M17.14M12.04M6.52M392K379K1.93M876K1.48M248K207K190K
Days Sales Outstanding1.29K------114.87278.8596.53105.57176.08265.4586.46117.2270.68256.4562.6964.5836.06
Inventory183K000001.35M1.15M52.51M443K1.13M472K568K0000000
Days Inventory Outstanding1.5-----306.05157.6937.43K150291.59165.497.76-------
Other Current Assets7.35M7.59M7.17M30.75M6.3M67K681K6.63M6.46M000120K86K000000
Total Non-Current Assets105.82M109.97M142.96M160.37M147.73M171.31M29.76M33.22M6.07M7.96M7.02M11.85M1.93M1.72M1.88M1.03M1.95M1.4M1.2M2.7M
Property, Plant & Equipment11.05M12.48M17.64M20.58M23.25M30.01M28.08M30.91M3.85M2.12M1.18M951K782K939K1.04M739K1.62M1.09M918K839K
Fixed Asset Turnover0.75x------3.62x7.77x30.56x35.24x14.21x0.69x1.70x5.81x6.12x1.30x1.33x1.27x2.29x
Goodwill00000000000000000000
Intangible Assets00000000000000000060K164K
Long-Term Investments94.77M0000001.15M1.15M5.83M5.83M10.68M00000000
Other Non-Current Assets097.49M125.32M139.79M124.48M141.31M1.68M1.16M1.07M00219K1.15M779K838K295K328K312K225K1.7M
Total Assets286.17M325.63M277.08M378.27M590.97M419.27M181.04M136.97M95.94M116.33M67.28M48.99M11.09M16.54M26.57M26.98M45.7M62.06M21.68M27.16M
Asset Turnover0.04x------0.82x0.31x0.56x0.62x0.28x0.05x0.10x0.23x0.17x0.05x0.02x0.05x0.07x
Asset Growth %-45.23%17.52%-26.75%-35.99%40.95%131.59%32.18%42.77%-17.53%72.91%37.32%341.79%-32.93%-37.78%-1.51%-40.96%-26.36%186.25%-20.18%-
Total Current Liabilities59.44M78.06M79.53M53.32M136.38M51.79M36.74M55.46M37.36M26.31M16.07M16.25M18.43M11.87M9.32M18.98M15.87M11.09M23.56M7.93M
Accounts Payable5.37M4.76M5.91M7.71M5.99M13.4M4.2M5.33M6.28M6.69M2.52M6.43M4.92M2.33M2.63M2M2.4M2.62M1.23M2.57M
Days Payables Outstanding258.25----3.53K948.41732.474.48K2.27K651.162.25K67.1246.3952.05K-----
Short-Term Debt26.27M17.06M21M8.58M94.38M003.5M889K490K198K73K6.45M5.6M05.89M395K4.93M16.56M1.01M
Deferred Revenue (Current)2.82M0000000-889K-490K-198K000970K5.75M8.01M702K232K500K
Other Current Liabilities14.1M48.79M29.51M07.82M3.71M3.95M43.08M26.58M16.46M8.61M2.52M001.42M4.98M4.09M01.78M1.56M
Current Ratio3.03x2.76x1.69x4.09x3.25x4.79x4.12x1.87x2.41x4.12x3.75x2.29x0.50x1.25x2.65x1.37x2.76x5.47x0.87x3.08x
Quick Ratio3.03x2.76x1.69x4.09x3.25x4.79x4.08x1.85x1.00x4.10x3.68x2.26x0.47x1.25x2.65x1.37x2.76x5.47x0.87x3.08x
Cash Conversion Cycle1.04K-------459.9233.24K-2.02K-254-1.91K206.09-------
Total Non-Current Liabilities290.06M368.8M380.16M349.94M368.9M343.7M265.06M190.53M-41.58M92.83M88.65M58.98M35.31M23.05M231.83M13.55M9.36M7.83M89.29M89.17M
Long-Term Debt278.76M208.53M166.58M329.7M220.91M313.46M236.29M158.21M148.98M83.31M79.51M49.77M26.26M14.9M20.1M13.55M9.36M7.83M118K0
Capital Lease Obligations32.07M7.25M13.47M18.14M22.43M29.13M28.77M32.32M1.58M810K324K206K00000000
Deferred Tax Liabilities00000000000000000000
Other Non-Current Liabilities5.7M153.02M200.11M2.09M125.57M1.11M008.18M8.72M8.82M9M9.05M8.15M3.69M00089.17M89.17M
Total Liabilities349.51M446.86M459.69M403.25M505.29M395.49M301.79M245.99M-4.22M119.14M104.72M75.23M53.74M34.92M241.15M32.54M25.23M18.92M112.85M97.1M
Total Debt310.63M239.14M207.02M361.58M342.02M347.84M268.84M194.03M151.45M84.61M79.71M49.84M32.71M20.5M20.1M19.45M9.76M12.76M16.67M1.01M
Net Debt308.73M229.48M203.62M354.48M331.01M247.03M258.34M190.95M145.59M81.21M77.49M48.48M32.35M19.11M18.58M15.44M6.48M11.94M3.95M-4.92M
Debt / Equity-4.90x---3.99x14.63x--0.23x-------0.48x0.30x--
Debt / EBITDA-2.98x-------------------
Net Debt / EBITDA-2.96x-------------------
Interest Coverage-17.81x--6.40x-9.93x-7.02x-8.74x-6.34x-2.73x-7.60x-3.85x-7.54x-20.02x-20.23x-15.82x-21.23x-14.15x-18.06x-9.43x-73.21x-151.92x
Total Equity-63.33M-121.23M-182.61M-24.98M85.68M23.78M-120.75M-109.02M650.13M-2.81M-37.45M-26.23M-42.65M-18.38M-214.58M-5.55M20.47M43.15M-91.17M-69.94M
Equity Growth %-22.59%33.61%-630.93%-129.16%260.32%119.69%-10.76%-116.77%23203.23%92.49%-42.74%38.5%-132.02%91.43%-3763.47%-127.13%-52.56%147.33%-30.35%-
Book Value per Share-1.00-1.91-3.14-0.401.370.38-2.11-2.2013.38-0.06-0.93-0.70-1.28-0.64-8.88-0.250.965.98-8.48-4.90
Total Shareholders' Equity-63.33M-121.23M-182.61M-24.98M85.68M23.78M-120.75M-109.02M650.13M-2.81M-37.45M-26.23M-42.65M-18.38M-214.58M-5.55M20.47M43.15M-91.17M-69.94M
Common Stock720K716K580K611K628K626K616K542K490K482K438K380K342K304K259K224K219K213K57K56K
Retained Earnings-857.63M-913.7M-910.35M-753.53M-635.72M-683.13M-872.67M-734.61M650.13M-523.37M-469.89M-403.14M-328.05M-254.37M-214.58M-176.13M-147.59M-118.34M-97.25M-73.42M
Treasury Stock00000000000000000000
Accumulated OCI00000000-4.25M-3.28M-2.73M-2.43M-2.23M-2.09M-1.79M-2.48M-2.08M41K-99K-4K
Minority Interest00000000000000000000

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Critical liquidity and dilution

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Persistent Negative Equity Erosion Trend

According to reported financial statements, Omeros has maintained a persistent negative equity position over the last ten quarters, with the deficit reaching $63.3 million in 2026Q1, reflecting a structural inability to generate retained earnings sufficient to offset the ongoing accumulation of losses from clinical development activities.

The consistent negative equity suggests that the company's capital base has been entirely depleted by years of R&D spending, leaving the balance sheet reliant on external financing to remain solvent. Investors should monitor whether the recent narrowing of this deficit indicates a genuine improvement in financial health or merely a temporary accounting artifact from non-operating adjustments.

High Leverage Amid Capital Constraints

Based on Omeros's reported figures, the company carries a significant debt load of $310.6 million as of 2026Q1, which, when viewed alongside its negative equity position, suggests a highly leveraged capital structure that may limit future financing flexibility and increase the risk of further shareholder dilution.

The reliance on debt to fund operations in the absence of positive cash flow creates a precarious situation where refinancing risk becomes a primary concern. The company's debt-to-asset profile appears to be driven by necessity rather than strategic growth, which may complicate future efforts to secure non-dilutive capital.

Critical Cash Runway and Solvency

As indicated by recent SEC filings, Omeros's cash and equivalents have dwindled to a precarious $1.9 million in 2026Q1, a level that appears insufficient to support the company's ongoing clinical trial obligations and suggests an immediate requirement for additional capital to avoid a liquidity crisis.

The current ratio of 3.03 may provide a misleading sense of security, as the underlying liquidity is heavily dependent on the timing of royalty receipts and potential asset divestitures. Given the high burn rate, the current cash position warrants extreme caution regarding the company's ability to maintain operational continuity without significant external intervention.

Non-Operating Distortions Masking Reality

Data from recent financial reports suggests that Omeros's balance sheet is heavily distorted by non-cash fair value adjustments on convertible notes, which can obscure the underlying operational reality of a company that has accumulated over $850 million in negative retained earnings as of 2026Q1.

These accounting adjustments often create volatility in the reported equity and net income figures that do not correlate with the company's actual cash-on-cash performance. Analysts should look past these non-operating items to focus on the core cash burn, which remains the most accurate indicator of the company's long-term viability.

OMER — Frequently Asked Questions

Quick answers to the most common questions about buying OMER stock.

What are the total assets of Omeros Corporation (OMER)?

As of 2025, Omeros Corporation (OMER) had total assets of $325.6M including $215.7M in current assets.

How much debt does Omeros Corporation (OMER) have?

Omeros Corporation (OMER) carries total debt of $239.1M, offset by $171.8M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Omeros Corporation?

Omeros Corporation (OMER) has total shareholders' equity (book value) of $-121.2M ($-1.91 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Omeros Corporation's current ratio and liquidity?

Omeros Corporation (OMER) reported a current ratio of 2.76x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.